Shandong Xinhua Pharmaceutical Secures Drug Registration for Icosapent Ethyl

Confident Investing Starts Here:

Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) has shared an announcement.

Shandong Xinhua Pharmaceutical Company Limited has announced that it has received the Drug Registration Certificate for its Icosapent Ethyl soft capsules from the National Medical Products Administration. This certification allows the company to proceed with the production and sale of the drug, which is expected to enhance its market presence and operational capabilities in the pharmaceutical sector.

More about Shandong Xinhua Pharmaceutical Company Limited Class H

Shandong Xinhua Pharmaceutical Company Limited is a pharmaceutical company based in China, focusing on the production and sale of prescription drugs. The company operates within the pharmaceutical industry and is involved in the development and marketing of chemical drugs, with a particular emphasis on domestic production.

Average Trading Volume: 4,260,784

Technical Sentiment Signal: Buy

Current Market Cap: HK$9.58B

Find detailed analytics on 0719 stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks’

Best Online Brokers

, and find the ideal broker for your trades.

Report an Issue

No Byline Policy

Editorial Guidelines

Corrections Policy

Source